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A new stcfin B-type 10~4~ CPI was isolated from bovine thymus and subjected to structural analysis. The inhibitor consisted of 98 amino acids 
and its Mr was calculated to be 11,178. The Nf-&-terminal mino acid residue was blocked. The sequence was determined by automated sequencing 
of peptides derived by cleavage with cyanogen bromide and fragments of the inhibitor resulting from enzymatic digestion with /I-trypsin and 
Sruphylococcur aweus V-8 proteinase. The NH+z-minal blocking group was established with mass spcctrometry. The inhibitor exhibits consid- 
erable sequence homology with inhibitors from the stefin family. Furthermore, a highly conserved QVVAG region within the sicfin family is for 
the first time replaced by the QLVAG sequence. 
St&n B; Cystatin; Cysteinc proteinasc inhibitor; Primary structure 
1. INTRODUCTION 
The inhibitors from the cystatin superfamily are re- 
versible, tight-binding inhibitors of the cysteine 
proteinases from the papain superfamily [I]. On the 
basis of sequence homology, the cystatin superfamily is 
divided into three families: Low-M, stefins, cystatins and 
high-Mr kininogens. Low-M, inhibitors are structurally 
different. The stefins with M, 11,000 lack disulflde 
bonds, while the cystatins with M, 13,000 have two 
intramolecular disulfide bonds (reviewed in [l-3]). The 
central QVVAG region is more conserved in the stefins 
than in the cystatins (reviewed in [4]). They also differ 
in their tertiary structure, the shorter helix nearer to 
COOH-terminus being present only in the cystatins 
[WI. 
The mammalian stefins have been isolated and char- 
acterized from human [7-l 31 and rat [14-l S] origins, but 
not from bovine origin. The only well-characterized 
bovine low-Mr CPI is bovine colostrum cystatin [19,20], 
which belongs to the cystatin family. 
Recently, we isolated a new low-Mr CPI from bovine 
thymus. Herein we present he complete amino acid 
sequence of bovine stefin B. It indicates homology to 
other known stefins, especially to human stefin B. 
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2. MATERIALS AND METHODS 
CM-papain Sepharosc was prepared as described [21]. Bovine stefin 
B was purified from bovine thymus using a pro&~ modified from 
that previously described [S]. Acetone precipitation was excluded and 
Sephadcx G-50 (Pharmacia. Sweden) was used instead of Sepbadex 
G-75. In the final step, the third inhibitory peak obtained by sep~m- 
tion on Scphadex G-50 was concentrated. ialyzed against 20 mM 
Tris buffer (pH 7.3) and chromatographed on DEAE-cellulose 
(Whalmann, USA) equilibrated with the same buffer. lnhibitors were 
eluted with a linear gradient of NaCI (O-O.3 M NaCI) in the same 
buffer. 1 .I mg of bovine stefin Band 2.5 mg of dimcric form of bovine 
stefin B was obtained. Inhibitor was sequentially pure. 
The isolated protein was reduced with/?-mercaptoethanol andcys- 
teine residues alkylated with 4-vinylpyridine (Fluka. Swilzertand) as 
described 1221. 
CNBr cleavage of PE-bovine stefin B was made in 80% formic acid. 
with a 50.fold molar excess of the reagent (Pierce. USA), under cduc- 
ing conditions. The rmction, which took place at room temperature 
in the dark for 24 h, was quenched with a IO-fold dilution of the 
reaction mixture with distilled water, and freeze dried. 
For enzymatic fragmentations of PE-bovine stetin BP-trypsin (EC 
3.4.21. I), prepared according to Strop and Cechova [23] and Sfrrplr.v- 
/ococcus uureus train V-8 proteinase (EC 3.4.21.19) from Miles (UK) 
were used. 
Hydrolysis by /?-trypsin was made on PE-bovine stcfin I3 and on 
maleylated PE-bovine stefin 8. Inhibitor was maleylated according to 
the proccdurc of Butler and Hartley [24]. The cleavage conditions in 
both cases were 0.1 M N-methyl-morpholinc a elate buffer, pH 8.12. 
at 37”C, and the fmal enzyme-to-substrate ratio was l:SO, Proteinase 
was added in two equal portions, at ~hc beginning and after 30 min 
of incubation. 
S. uwws V-8 prouinase cleavage was performed on malcylated 
PE-bovine stcfin B in 0. I M ammonium acetate butler, pH 4.0. at 37°C 
for 24 h with 2% (w/w) of protcinasc. 
After enzymatic cleavages of maleylated PE-bovine SItfin B. 
samples were demalcylatecl byacidification of the reaction mixlurcs 
to pH 3.5 with TFA and incubation at 37°C for another 48 h. 
NH,-terminal peptidc for mass pectrometer analysis was obtained 
from the native bovine steiin B afirr the cieauage with PP IV, a 
generous gift of Dr. Allan J. Barrett. The incubation buffer was 0.1 
M Na phosphate, I mM EDTA. 2 mM DTT, pH G.SI. Reaction 
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proceeded at room temperature for 24 h with the enzyme-to-substrate 1 10 20 30 40 50 
mass ratio I :50. aMMCGGTSATQPATA~TQAIADKVKSQLIEKENKKFPVFKALEFKSQLVAG 
Peptidr purification was performed by HPLC (Milton Roy, USA) 
on Chrompack ChromSpher C8 and Cl8 columns (100 x 3 mm) 
equilibraled with 0.1% TFA in water, and &ted by linear gradients 
to 80% acetonitrile and 0.1% TFA in water. The flow rate was 1 
ml/min. Absorbance was monitored at 2 15 nm. 
Amino acid analyses of pcptide hydrolysstcs, obtained wilh 6 M 
HCI at llO”C, were done wilh HPLC (Pharmacia LKB. Sweden), 
using n LKB EupcrPac ODS? column and pre-column o-phthnlal- 
dchydc drrivatization, 
pptl, 
CN3 
T5 T6 
-E5 
60 70 80 
HNY~:KYQVDLDDF"H~R"FESLPHENKPVALT6YQ~N~~~D~LTYF 
, TB , TlO 
aE5 ' , E6 B 
, Tll 
__ , T12 : , ‘rn2 I 
Primary structure was determined with an Applied Biosystems: 
(USA) liquid-pulsed sequencer 470A. on-line conncctcd to a 1lOA 
PTH amino acid analyscr of the same manufacturer. 
Mass spectrometer analysis was made on an Autospec Q mass 
spectrometer (VG-Analytical, UK), using the FAD ionization method. 
Glycerol was used as matrix. 
3. RESULTSANDDISCUSSION 
Ala A 8 Gln Q 9 LSU L 6 SQT 6 5 
Arg R 2 Glu E 6 LyB K 11 ThrT 7 
Asn N 4 GlyG 4 M&M 2 Tyr Y 3 
Asp D 5 His H 3 PhQ F I va1v 8 
cys c 1 11e I 3 Pro P 4 
total: 98 residues; M,: 11178 
When the native, intact bovine stefm B was applied 
to the sequence analysis no amino acid residue could be 
detected, indicating that the inhibitor was blocked at the 
NH,-terminal. Attempts to remove the blocking group 
under the deformylating conditions (1.5 M HCI for 30 
min at 25OC) were unsuccessful. 
Fig. 1, The amino acid sequence and composition of bovine stciin 9. 
CN-pcptide is from CNl3r cleavage, T-pcptides from the &tryptic 
fragmcnlation, TR-peptide from the limited ~lryptic hydrolysis, E- 
pcptides from S. umm protcinase cleavage and PDI-peptidc from 
papaya proteinasc IV digestion of the inhibitor. 
CNBr cleavage gave only one large peptide of 
virtually the same size as uncleaved PE-bovine stefin B 
but it was not blocked anymore, as was indicated by 
sequence analysis. It was sequenced to residue 43 (CN3 
in Fig. 1) starting with the Cys amino acid residue. In 
the first sequencing cycle Met was also detected (about 
5% with respect o Cys). As amino acid analysis of the 
native inhibitor gave a Met value of 2, the conclusion 
was that the additional Met resulted from the uncom- 
pletc c,‘NBr cleavage following two successive Met 
residues iocated at the NH?-terminal of the molecule. 
Met-Met sequence was NH,-terminally blocked. 
ing part of the structure (residues 80-89) and overlap 
with the COOH-terminal peptide Tl 1 (residues 90-98) 
(Fig. 1). 
Overlapping peptides for the central part of the mol- 
ecule (E5 and E6 in Fig. 1) were obtained with the S. 
aureus proteinase. PE-bovine stefin B was maleylated 
before cleavage in order to achieve complete denatura- 
tion and therefore better access of the proteiaase. 
In order to establish the blocking group, NH,-ter- 
minal peptide of appropriate length for mass spectro- 
meter analysis was prepared with PP IV fragmentation 
of the native bovine stefin B (PPI in Fig. 1). The PPl- 
peptide mass spectra gave the M,tI value of 483 Da, 
which together with its amino acid analysis revealed the 
N-acetylation as in the highly homologous rat cystatin 
P [Ia. 
Twelve peptides were isolated from the cleavage of 
PE-bovine stefln B with ,&trypsin (T-peptides) and char- 
acterized, but only those important for establishing the 
primary structure of the inhibitor are shown in Fig. 1. 
TlO peptide (residues 69-89) could not be completely 
sequenced because the reaction yield fell drastically 
after Pro”. Peptides Tll and T12 ended with Phe, and 
since the COOH-terminal Phe residue would not have 
been a site of cleavage by ,&trypsin they correspond to 
the COOH-terminus of the molecule. 
Ma!ey!ation of Lys a.mino acid residues in PE-bovine 
stefin B restricted the tryptic cleavage only after Arg 
amino acid residues. Three peptides were obtained (TR- 
peptides). Only TR2 was sequenced to provide the miss- 
The results show that the inhibitor consists of 98 
amino acid residues (Fig. I) with M,. of 11,178. In Fig. 
2 the amino acid sequence of bovine stefin B is aligned 
with some other sequences in the stefin family. The 
present sequence ie 77.5% identical with that of human 
stefin B, 71.4% with that of rat cystatin /?, and 48.9% 
with that of human stefin A. The sequence comparison 
indicates that it belongs to the stefin B subgroup of the 
stefin family. The most interesting feature in the bovine 
stefin B sequence is the difference in the well-conserved 
QVVAG region in the stefins of mammalian origin (Fig. 
2): Va15” (chicken cystatin numbering) is replaced with 
I,,e$‘. From the determined X-ray crystal structures of 
chicken cystatin [5] and human stefm B-papain com- 
plex [6] it is evident that this region folds into an ex- 
posed ‘first’ hairpin loop which is flanked on both sides 
by the amino-terminal segment and the ‘second’ hairpin 
loop. The main hydrophobic interactions are provided 
by the ‘first’ hairpin loop. It was shown recently [25-271 
that some exchanges of amino acids within this region 
in the recombinant stelins have only minor effect on the 
inhibitory activity indicating that the conserved 
QWAG region is not essential. Our result shows that 
also natural inhibitor with a mutation in this otherwise 
strictly conserved region within the stefin family exists. 
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1 10 20 30 40 40 
BOV.STEF. B aNNCGGTSATQPATAETQASADKVKSQLEEKENKKFPVFK 
HUN.STEF. B xM*+*AP****ar*****H***Q*R**~***y*********V~~***V*** 
RAT CYST. R aM***Ap***M***T***E**r*******~*k*A*Q**n**~*IS*~*V**~ 
HUN.STEF. A MIP*rLn~***P*T*E*Vaanap***t*T+ETYGKLEay*T*V*** 
60 70 
BOV.STEF. B KNYFIKVQVDEDDFVHIRVFESLPHENK~~ALTSYQTN~:FfHDELTYF 
HDH.STEF. B T*****!*H*GDE**r*L*A*Q**~*****LT*&N*****~******* 
RAT CYST. I?I T*F****D*G*EKC*aL+**~P*~****D*******~ 
HtiH.STEF. A T**Y***RAGDN*YM*LK**K***GQ*EDLV*TG**VD*NKD****G* 
Fig. 2. Alignment of amino acid scqucnces ofbovine stefin B with those of human stcfin B [I 21, rat cystatin p [ 181 and human stcftn A il3]. Residues 
identical to those in bovine stefin B are marked with an asterisk (*), numbering is according to human stefin B. 
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